Stable and Bio-Equivalent Formulation of Alginate Matrix-Based Verapamil Hydrochloride Extended-Release Tablets

Pharmaceutical Science-Industrial Pharmacy

Authors

  • Packiaraj Jeyachandran Manohari Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India. https://orcid.org/0000-0001-7082-648X
  • Venkateswaran Chidambaram Seshadri Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India.
  • Narendra Reddy Parvatha Janarthana Reddy Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India.
  • Janakiraman Kunchithapatham Professor and Head of the Department, Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram, Cuddalore District, Tamil Nadu – 608002, India
  • Harshavardhana Reddy Venkatarangareddy Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India.
  • Guhan Himadeep Chowdary Eswara Rao Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India.
  • Sumathi Vinay Rao Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India.
  • Subham Jain Naveen Kumar Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India.
  • Srihari Teja Seelamantula Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Private Limited, Thiruvandavar Village, Sirupinayur Panchayat, Uthiramerur Taluk, Kanchipuram District, Chennai, Tamil Nadu – 603308, India.

DOI:

https://doi.org/10.22376/ijpbs/lpr.2022.12.6.P240-249

Keywords:

extended release matrix tablet, pharmacokinetics and, pharmaco-economics.

Abstract

Verapamil Hydrochloride is indicated to control blood pressure in individuals due to postural and nocturnal–diurnal variations in the biological clock. The once-daily administration of Verapamil Hydrochloride is handy for patients to comply with the dosing regimen prescribed. This research aims to develop stable, bio-equivalent, cost-effective, and commercially feasible Verapamil Hydrochloride extended-release tablets, 120 mg, 180 mg and 240 mg. Inorder to achieve this aim, our objective was to explore a simple aqueous granulation involving conventional excipients viz. Sodium Alginate, Povidone, Microcrystalline Cellulose and Magnesium Stearate. The drug to polymer ratio of 1:1.35 was found to be optimum. Every unit operation involved in the process was completely optimized to achieve reproducibility and to avoid drug release variation. The designed process was scaled-up from a batch size of 75,000 tablets to 750,000 tablets. During scalability, no difference is observed in the physico-chemical characteristics of the blend or tablets. The blend and content uniformity results were found to comply with USP requirements. The manufactured product was found stable in bottle and strip packs at accelerated stability conditions for 6 months. The maximum level of the highest unknown impurity observed was 0.1% and is well within the ICH Q3BR3 requirements. Hence based on stability study results, shelf-life storage of 24 months at controlled room temperature was prescribed for the product. The end product was found to be more cost-effective (3.2 to 6.4 Indian rupees) than the brand product available nationally (within India) priced at 4.7 to 9 Indian rupees, and the physico-chemical characteristics, drug release, and stability of the manufactured drug product were comparable to the brand product available in the USA market. The similarity factor 'f2' was found to be more than 75. In the Pharmacokinetic study, the test to brand product ratio at 90% confidence interval was within 80.00-125.00%, exhibiting the developed product's bio-equivalence with the brand product. Novelty in this research is in the comprehensiveness of work done to demonstrate stability, bio-equivalence, cost-effectiveness and commercial ability aspects which were not reported elsewhere in the already published research work on Verapamil extended release tablets. 

References

Verapamil HCl topical use in Peyronie’s, plantar fibromatosis, Dupuytren’s[internet][retrievedApr72022]Available from: pdlabs.

Verapamil HCl[internet][citedApr72022].Available from: Drugs.com.

Securon SR-SPC[internet][citedApr72022].Available from: medicines.org.uk.

Calan-verapamil HCl tablet[internet][retrievedApr72022]Available from: dailymed.

Verapamil HCl[internet][citedApr72022]. Available from: http://ema.europa.eu/.

Schroeder JS, Frishman WH, Parker JD, Angiolillo DJ, Woods C, Scirica BM. Ischemic disease. A companion to Braunwald’sheart disease. Elsevier;2013. p. 83-130.

Verapamil HCl[internet][retrievedApr72022]Available from: ASHSP.

Tfelt-Hansen PC, Jensen RH. Management of Cluster headache. CNS Drugs. 2012;26(7):571-80. doi: 10.2165/11632850-000000000-00000, PMID 22650381.

Merison K, Jacobs H. Migraine diagnosis,treatment. CurTrOpNeu;48:2016.18(11).

WHO. WHOmodelformulary2008. WHO. hdl:10665/44053Stuart MC, Kouimtzi M, Hill SR, editors. ISBN 9789241547659; 2009.

Isoptin:drugs@fda [internet][retrievedApr72022]Available from: drugs@fda.

WHO model list of essential medicines: 21st list 2019. Geneva: WHO. hdl:10665/325771[internet][retrievedApr72022].

WHO model list of essential medicines: 22nd list;2021. WHO. hdl:10665/345533[internet][retrievedApr72022].

The top 300 of 2019[internet][retrievedApr72022]Available from: ClinCalc.

Verapamil – drugstatistics [internet][retrievedApr72022]Available from: ClinCalc.

Koda-Kimble and Young’sappliedtherapeutics: theclinicaluse of drugs.10thed. Vol. 2012. Lippincott Williams & Wilkins;1349. ISBN 978-1609137137. p. 497.

Srinivasan V, Sivaramakrishnan H, Karthikeyan B. Impurities in verapamil HCl. Sci Pharm. 2011;79(3):555-68. doi: 10.3797/scipharm.1101-19, PMID 21886903.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler Jet al.Management of high BP. JAMA. 2014;311(5):507-20. doi: 10.1001/jama.2013.284427, PMID 24352797.

Koda-Kimble and Young’sappliedtherapeutics: theclinicaluse of drugs. LWW Tenth North AmEd. 2012:320-22. ISBN 978-1609137137.

Beck E, Sieber WJ, Trejo R. Management of cluster headache. Am Fam Physician. 2005;71(4):717-24. PMID 15742909.

Jun P, Ko NU, English JD, Dowd CF, Halbach VV, Higashida RT. treatment of cerebral vasospasm. Am J Neu Res.2010;31(10):1911-6.

Drislane F, Benatar M, Chang BS, Acosta J, Tarulli A. Blueprints neurology. Lippincott Williams & Wilkins. ISBN 978-0-7817-9685-9; 2009. p. 71.

Young JR, Sternbach S, Willinger M, Hutchinson ID.RosenbaumAJ.plantar fibromatosis etiology, evaluation, and management. Orthop Res Rev. 2018;11:1-7.

Securon. 2.5 mg/ml IV. SPC[internet][citedApr72022].Available from: medicines.org.uk.

Krevsky B, Maurer AH, Niewiarowski T, Cohen S. Verapamil on intestinal transit. Dig Dis Sci. 1992;37(6):919-24. doi: 10.1007/BF01300391, PMID 1587197.

Steele RM, Schuna AA, Schreiber RT. Verapamil HCl in gingival hyperplasia. Ann InternMed. 1994;120(8):663-4. doi: 10.7326/0003-4819-120-8-199404150-00006, PMID 8135450.

Wilimowska J, Piekoszewski W, Krzyanowska-Kierepka E, Florek E. Verapamil enantiomers in overdose. Clin Toxicol (Phila). 2006;44(2):169-71. doi: 10.1080/15563650500514541, PMID 16615674.

Baselt R.Toxic Drugs disposition. 8th ed;2008. FosterCity C.Biomed Pub. pp. 1637-39.

Wang SP, Wang JA, Luo RH, Cui WY, Wang H. Potassium channel in rat mesenchymal stem cells in cell proliferation. Clin PharmPhysiol. 2008. Sep;35(9):1077-84.

Petersen AS, BarloeseMCJ, Snoer A, SoerensenAMS, Jensen RH. Verapamil and clusterheadache: Still a Mystery. A Narrative Review of Efficacy, Mechanisms and Perspectives. Headache. 2019;59(8):1198-211. doi: 10.1111/head.13603, PMID 31339562.

Giannini AJ, Houser WL, Loiselle RH, Giannini MC, Price WA. Antimanic effects of verapamil. Am J Psychiatry. 1984;141(12):1602-3. doi: 10.1176/ajp.141.12.1602, PMID 6439057.

Giannini AJ, Taraszewski R, Loiselle RH. Verapamil and lithium in manic patients. J Clin Pharmacol. 1987. Dec;27(12):980-2. doi: 10.1002/j.1552-4604.1987.tb05600.x, PMID 3325531.

Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M. Magnesium oxide and verapamil in mania. PsycholRes.2000;93(1):83-7.

Elferink JG, Deierkauf M. Verapamil on polymorphonuclear leukocytes. Bio Pharm. 1984;33(1):35-9.

Azzarone B, Krief P, Soria J, Boucheix C. fibroblast-induced clot retraction by verapamil and ALB6. J Cell Physiol. 1985. Dec;125(3):420-6. doi: 10.1002/jcp.1041250309, PMID 3864783.

Steinleitner A, Lambert H, Kazensky C, Sanchez I, Sueldo C. Verapamil for postoperative adhesion in rabbit. J SurgRes. 1990;48(1):42-5. doi: 10.1016/0022-4804(90)90143-p, PMID 2296179.

Baxter GM, Jackman BR, Eades SC, Tyler DE. Verapamil for abdominal adhesions. Vet Surg. 1993;22(6):496-500. doi: 10.1111/j.1532-950x.1993.tb00427.x, PMID 8116206.

Song J, Chang I, Chen Z, Kang M, Wang CY. Characterization of side populations in HNSCC: highly invasive, chemoresistant and Abnormal Wnt signaling. PLOS ONE. 2010;5(7):e11456. doi: 10.1371/journal.pone.0011456, PMID 20625515.

Bellamy WT. P-gP and drug resistance. Annu Rev PharmacolToxicol. 1996;06:161-83.

Verapamil[internet][retrievedApr72022]Available from: medlineindia.

Calan SR[internet][citedApr72022].Available from: drugs.com.

VerapamilERTab [internet][Retrieved 7th Apr‘2022].Available from: lubrizol.com.

Reddy KR, Rathnam G, Kiran I, Raju S,Mulpuri KS.SR matrix tablets of verapamil HCl. IJPSR.2014;5(5):2066-73.

BaichwalAR, StaniforthJN.CRverapamil tablets. Pat Date. US patentPatno. 5169639. Dec8, 1992:1-14.

BrijeshR, Gupta MM. Verapamil HClSR matrix tablet. J Drug DelivTher.2013;3(1):55-8.

KimlekT, PrasertpornT, SawantranonJ, SriwichupongChaisan.Garnpimol Ritthidej, CR tablets of verapamil HCl.Asian J Pharm Sci.2015.

GulianFJ, TiwariSB, SimonBH, FerrizziD,Rajabi-SiahboomiA.VerapamilER matrix. American Association of Plastic Surgeons;2006[internet][retrievedApr72022].

Kulkarni D, Dwivedi AK, Sarin JPS,Singh S. Tamarind seed polyose for SR of verapamil HCl. Ind J Pharm Sci.1997;59(1):1-7.

El‐GazayerlyON, Rakkanka V, Ayres JW. Novel chewable sustained-release tablet containing verapamil hydrochloride. Pharm Dev Technol. 2004;9(2):181-8. doi: 10.1081/pdt-120030248, PMID 15202577.

Khamanga SMM. VerapamilSRtablets. A Thesis; ’2005[internet]. Feb[citedApr72022]. Available from: core.ac.uk.

Sahoo J, Murthy PN, Biswal S, Manik. Verapamil HClSR by solid dispersion. AAPS PharmSciTech. 2009;10(1):27-33. doi: 10.1208/s12249-008-9175-0, PMID 19145487.

Ullaskumar S, Ramu B, Srikanth G, Bigalarajkamal. Verapamil HClSR using Natural polymers. Int J ApplPharmSci Res.2016;1(2):76-87.

Vidyadhara S, SasidharRLC, RaoVM, BabuCHS, Harika DL. Verapamil HCl osmotic CR tablets. Asian J Pharm.2014;8(2):102-9. doi: 10.4103/0973-8398.134941.

Irfanbashir A,Muhammadzaman J,RaiM. Sarfraz,Asifmahmood,MuhammadI.Sajid, Talhajamshaid, MuhammadA.Akram. Verapamil HCl matrix tablets. Int CurrPharmJ.2014;3(6):286-90.

BhagwatDA, KawtikwarPS, Dinesh M. Sakarkar. SRmatrices of verapamil HCl. ResJPharm Technol.2008;1(4):405-9.

PatidarD, ShahSK, Tyagi CK, PandeyH. CR effervescent floating tablet of verapamil HCl. JPharmSci Res. 2016;8(8):732-40.

AnushaK, KalyaniV. Kola venu. SR Matrix tablets of verapamil HCl. Wo J Pharm PharmSci. 2019;8(5):1633-44.

SiahiMR, Barzegar-JalaliM, MonajjemzadehF, GhaffariF, AzarmiS. Multilayer matricesofVerapamilHCl.AAPSPharmSciTech. 2005:E626-32.

PansareJJ, SurawaseRK. Fast disintegratingSRpellets of verapamil HCltablets. As J Res Pharm Sci.2021;11(4):261-6.

AnepuS, Lohithasu Duppala PPV. SR tablets of verapamil. J Appl Pharm Sci.2015;5(12):125-34.

ShaikI, Harish G, Pragati Kumar B, Abhilash T. Osmotic CR of verapamil HCl. Ind J Res Pharm Biogr.2014;2(6):1465-9.

Sailaja R, Deepthi KL, Jagdeesh Panda NVVS, Navya PV, Himabindhu CH, Sri Vihari V. Floating tablets of verapamil HCl. Int J PharmSciInv.2021;10(9):1-6.

KhanA, IqbalM.Jallat khan, Gul Majid Khan, Muhammad Hanif, Amjad Khan. SR matrix tablets of Verapamil HCl. Lat Am J Pharm.2015;34(2):277-82.

BhukyaN, DhurkeR. Gastroretentive mucoadhesive pulsatile tablet of verapamil HCl. J Chem Pharm Res.2016;8(8):1190-8.

GleixnerK, LehrachRMF.CRverapamil tablets. Pat Date. US patentPatno. 4189469. Feb19, 1980:1-5.

DunnJM.CR formulations of verapamil. Pat Date. US patentPatno. 4461759. Jul24, 1984:1-5.

StephensSI,Hamel LG.Verapamil dosage form. Pat no. 4753802. Pat Date. Jun28, 1988:1-7.

HowardJR,TimminsP.CR formulation of verapamil. Pat no. 4792452. Pat Date. Dec20, 1988:1-5.

BaudierP, De BoeckA, FossionJ.Galenic forms of Prolonged release verapamil. Pat no. 4832958. Pat Date. May23, 1989:1-13.

BaudierP, De BoeckA, FossionJ.Novel Galenic forms of verapamil their preparation. Pat no. 4859469. Pat Date. Aug22, 1989:1-11.

PanozDE, GeogheganEJ.CR formulation of verapamil HCl. Pat no. 4863742. Pat Date. Sep5, 1989:1-25.

BalzE, EinigH, DresenP.CR formulation of verapamil HCl. Pat no. 5132295. Pat Date. Jul21, 1992:1-4.

EinigH, StierenB, BuehlerV, HollmanM.CR formulation of verapamil HCl. Pat no.5230901. Pat Date. Jul27, 1993:1-3.

PowellTC.CR formulation of verapamil HCl. Pat no.5252337. Pat Date. Oct12, 1993:1-8.

Verapamil HCl[internet][citedJul 72022].Available from: pharmacopeia.cn.

VerapamilER Tab[internet][citedJul 72022].Available from: pharmacopeia.cn.

KharRK, Vyas SP, AhmadFJ, JainGK. Lachman/Lieberman’s Industrial Pharmacy. 4thed. 7th Reprint. 2022. India:CBS. pp. 67-85.

Viscosity by Brookfield[internet][retrievedJul72022]Available from:brookfieldengg.

AwadH, AbouleneinHY. Determination of sodiumalginate by HPLC. J Chr Sci.2013;51:208-14.

Jones SA, Martin GP, Brown MB. Determination of PVP using HPLC. JPBio An. 2004. 28;35(3):621-4.

ZhangC, YangJ, QiaoL.Estimation of microcrystallinecellulose, J AOAC. J AOAC Int. 2011;94(2):660-3. PMID 21563704.

Arai T, Hosoi Y. Determination of magnesium stearate using HPLC. Yakugaku Zasshi:2005.125(3):299-305. Japanese.

BansalAK, KoradiaV.Reverse engineering in generics. Pharm Technol. 2005;29(38).

Mitra B, Hilden J, Litster J.LitsterJ.Intra and extragranular intablet. J Pharm Sci. 2018;107(10):2581-91. doi: 10.1016/j.xphs.2018.05.011, PMID 29803616.

ChingAL, LiewCV, ChanLW, Sia HengPW.Matrix pH from alginate matrices.Eurjpharmsci2008. p. 361-70.

Tolia G, Li SK. Silicone matrix of verapamil. AAPS PharmSciTech. 2014Feb;15(1):1-10. doi: 10.1208/s12249-013-0004-8, PMID 24022347.

EKNjega, SMMaru, LTirop. The binder effect of povidone. MaterSci. 2015.

ChaerunisaaAY, SriwidodoS, AbdassahM. Microcrystalline cellulose.Pharmform RecPrac.2019.1-21.

Uzunović A, Vranić E. Effect of magnesium stearate on dissolution. Bosn J Basic Med Sci.2007Aug;7(3):279-83. doi: 10.17305/bjbms.2007.3060, PMID 17848158.

Opadry II. Film coating [internet][retrievedJul72022]Available from: colorcon.

Security screening [internet][retrievedJul 72022]Available from: quadro-tech.

Shanmugam S. Granulation techniques and technologies: recent progresses. BioImpacts. 2015;5(1):55-63. doi: 10.15171/bi.2015.04, PMID 25901297.

ThapaP, Du HyungC, SooKM, HoonJS. Granulation process onphysicalproperties.AsianJPharmSci. 2019;14(3):287-304.

Amperage[internet][retrievedJul 72022].Available from: pharmamanual.com.

PauliV, KleinebuddeP, KrummeM. Pharma granulation and drying. Pharmaceutics. 2020;12(1):1-11. doi: 10.3390/pharmaceutics12010067, PMID 31952206.

Kotamarthy LVG. Granulation and milling effect on granule quality. A Thesis; ’2018[internet][Retrieved7Apr’22]. Jan. Available from: rucore.libraries.rutgers.edu.

ShahJ, TomarM, SinghAK, SinhaAR. Microcrystalline cellulose as lubricant like magnesiumstearate. Int J Dev Res.2017;7(10):15879-84.

Dun J, Chen H, Sun CC. Tabletability deterioration of Microcrystalline cellulose by magnesiumstearate. Int J Phys.2020.

Pingali K, Mendez R, Lewis D, Michniak-Kohn B, Cuitino A, Muzzio F. Mixing of glidants and lubricant.IJP.2011.409;1-2:269-77.

ScheibelhoferO,BalakN,WahlPR,KollerDM,GlasserBJ,KhinastJG. Powderblending.AAPS PharmSciTec.2013.14 (1):234-44.

Natoli D, Levin M, Tsygan L, Liu L. Development, optimization, scaling-up oftabletting. Developing solid oral dosage forms. 2nded. Pharmaceutical theory and.

Uebbing L, Klumpp L, Webster GK, Löbenberg R. Justification of disintegrationtesting beyond current FDA criteria using in vitro and in silico models. Drug Des Dev Ther.2017;11:1163-74. doi: 10.2147/DDDT.S131213, PMID 28442890.

Janakiraman KK, Paramaguru R, Janakiraman K. Dexibrufen formulation.Int J Life Sci Pharm Res. 2020;10(5):178-90.

Joan Vijetha R, Balamurugan K. Enalaprilmucoadhesivetablet. IntJ Life SciPharma.

Vivekanandan S, LindholmB, Raghunandan Reddy K, Venkatesan P. Chitosan – dexibuprofennanoparticles.IntJ Life SciPharm Res. 2021;11(6):48-57.

PalSovanL, Manna PK, Mohanta GP. Carvedilol – PLGAnanoparticles;2018.

Sritharan S, Narayanan N. VenlafaxineERtablets. Int J Pharm Sci Rev Res:2012.13(1), 149-53.

Dimitrov M, Lambov N. Study of verapamil – Polyox-Wsr tablets. IntJPharm. 1999;189(1):105-11. doi: 10.1016/s0378-5173(99)00242-2, PMID 10518690.

Alcohol dose dumping study[internet][citedJul 72022].Available from:https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204683.pdf.

Divisibility or Split study[internet][citedJul 72022].Available from:https://www.fda.gov/media/81626/download.

Pharmacoeconomics[internet][citedJul 72022].Available from:https://pharmafranchisehelp.com/how-to-calculate-mrp-ptr-pts-pharma-franchise/.

Towse A, DrummondM, SorensonC. Pharmacoeconomics. In: DanzonPM, NicholsonS, editors, The Oxfordeconomics of biopharmaindustry;2012. doi: 10.1093/oxfordhb/9780199742998.013.0013.

Published

2022-10-18

How to Cite

Manohari, P. J. ., Seshadri, V. C. ., Janarthana Reddy, N. R. P. ., Kunchithapatham, J. ., Venkatarangareddy, H. R. ., Chowdary Eswara Rao, G. H. ., Rao, S. V., Naveen Kumar, S. J. ., & Seelamantula, S. T. . (2022). Stable and Bio-Equivalent Formulation of Alginate Matrix-Based Verapamil Hydrochloride Extended-Release Tablets: Pharmaceutical Science-Industrial Pharmacy. International Journal of Life Science and Pharma Research, 12(6), P240-P249. https://doi.org/10.22376/ijpbs/lpr.2022.12.6.P240-249

Issue

Volume 12 Issue 6, November 2022

Section

Research Articles

Copyright (c) 2022 Packiaraj Jeyachandran Manohari, Venkateswaran Chidambaram Seshadri, Narendra Reddy Parvatha Janarthana Reddy, Janakiraman Kunchithapatham, Harshavardhana Reddy Venkatarangareddy, Guhan Himadeep Chowdary Eswara Rao, Sumathi Vinay Rao, Subham Jain Naveen Kumar, Srihari Teja Seelamantula

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.